novo nordisk cagrilintide flags promise in hunt for next obesity drug Novo Nordisk Files NDA for

Novo Nordisk Files NDA for CagriSema, Novel GLP 1 amylin Combination for Chronic Weight Management Patient Care Online A new drug combo of semaglutide (GLP 1 receptor agonist) with cagrilintide (amylin analogue) failed to do as well as tirzepatide (GLP 1 GIP receptor agonist). The future of these medicines is hitting different receptors. Another obesity contender just raised the stakes. Novo Nordisk's CagriSema combination delivered around 20% mean weight loss in a large trial. The formula combines semaglutide with cagrilintide, giving the body multiple appetite control Novo Nordisk files for FDA approval of CagriSema, the first once weekly combination of GLP1 and amylin analogues for weight management

SKU: 85745813519 · From iglepidom.org